Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis (RA) patients discontinue or change therapy within the first year of treatment.
Jun 13, 2013
0
0
A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients ...
Jun 8, 2012
0
0
Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab (which targets tumour necrosis factor alpha), but at considerable cost. A recent analysis ...
Mar 3, 2017
0
3
Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients ...
Jun 8, 2012
0
0
Tumour necrosis factor (TNF), a messenger substance in the immune system, plays an important role in triggering chronic inflammatory diseases. For this reason, TNF inhibitors are a standard form of treatment for patients ...
Jul 11, 2016
0
1
According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment ...
Jun 8, 2012
0
0
The results of a UK study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that tumour necrosis factor inhibitor (anti-TNF) treatment is effective at improving both muscle and ...
Jun 10, 2016
0
2
